FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Phillip Holler

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Mouse

Genes & Molecular Sequences

Concepts & Ideas

Models, Molecular

Physiology

Procedures

Directed Molecular Evolution

Co-author Network

Publications

TOP 3
Adam S Chervin; Jennifer D Stone; Phillip D Holler; Ailin Bai; Jianzhu Chen; Herman N Eisen; David M Kranz
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.
Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.
Lukasz K Chlewicki; Phillip D Holler; Bridget C Monti; Matthew R Clutter; David M Kranz
High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Phillip Holler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Adam S Chervin; Jennifer D Stone; Phillip D Holler; Ailin Bai; Jianzhu Chen; Herman N Eisen; David M Kranz
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(2):1166-78.
2007: Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.
Molecular immunology 2007;44(9):2184-94.
2005: Lukasz K Chlewicki; Phillip D Holler; Bridget C Monti; Matthew R Clutter; David M Kranz
High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3.
Journal of molecular biology 2005;346(1):223-39.
2004: Kah-Whye Peng; Phillip D Holler; B A Orr; David M Kranz; stephen russell
Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor.
Gene therapy 2004;11(15):1234-9.
2004: Phillip D Holler; David M Kranz
T cell receptors: affinities, cross-reactivities, and a conformer model.
Molecular immunology 2004;40(14-15):1027-31.
2003: Jens A Leifert; Phillip D Holler; Stephanie Harkins; David M Kranz; J Lindsay Whitton
The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes.
Gene therapy 2003;10(25):2067-73.
2003: Phillip D Holler; David M Kranz
Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation.
Immunity 2003;18(2):255-64.
2003: Susan E Brophy; Phillip D Holler; David M Kranz
A yeast display system for engineering functional peptide-MHC complexes.
Journal of immunological methods 2003;272(1-2):235-46.
2003: Phillip D Holler; Lukasz K Chlewicki; David M Kranz
TCRs with high affinity for foreign pMHC show self-reactivity.
Nature immunology 2003;4(1):55-62.
2001: Phillip D Holler; A R Lim; BK Cho; LA Rund; David M Kranz
CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation.
The Journal of experimental medicine 2001;194(8):1043-52.
2000: EV Shusta; Phillip D Holler; Michele C Kieke; David M Kranz; K Dane Wittrup
Directed evolution of a stable scaffold for T-cell receptor engineering.
Nature biotechnology 2000;18(7):754-9.
2000: Phillip D Holler; P O Holman; EV Shusta; SM O'Herrin; K Dane Wittrup; David M Kranz
In vitro evolution of a T cell receptor with high affinity for peptide/MHC.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(10):5387-92.
1999: LA Rund; BK Cho; TC Manning; Phillip D Holler; Edward J Roy; David M Kranz
Bispecific agents target endogenous murine T cells against human tumor xenografts.
International journal of cancer. Journal international du cancer 1999;83(1):141-9.